Items of recent pandemic news: Monitoring sewage for Covid early warning; therapeutics in short supply; a variant of little concern; antigen tests may miss early infectivity; Pfizer boost authorized for 12-15-year-olds; and more. Plus a frippery. Quote of the week … Continue reading →
The FDA has issued an emergency use authorization for Merck’s Molnupiravir, an oral antiviral to prevent mild or moderate Covid-19 from progressing to more serious disease, for those aged 18+ for whom other treatment options are not accessible / appropriate. … Continue reading →
The Food and Drug Administration has issued an emergency use authorization for Pfizer’s Paxlovid (nirmatrelvir and ritonavir), an oral antiviral to prevent mild or moderate Covid-19 from progressing to more serious disease. Supplies will be severely limited for now. Paxlovid … Continue reading →
Items of recent pandemic news: Those who pay zero attention to the pandemic; the evolutionary weirdness of Omicron; the class-based roots of vaccine avoidance; boosters authorized for people aged 16-17; and Paxlovid’s continuing promise. Plus a frippery. Paxlovid holds up … Continue reading →
Items of recent pandemic news: The Great Resignation among healthcare workers; the CDC may stop talking about herd immunity; the sobering prevalance of long Covid; the fifth pandemic wave crashing over Europe; and considerations for oral antivirals. Plus a frippery. … Continue reading →
Items of recent pandemic news: the US government buys more of Merck’s molnupiravir; a possible shortage of syringes looms next year; how Covid-19 affects the heart; and a pause in the administration’s vaccine mandate for companies. Plus a frippery. Biden’s … Continue reading →
Items of recent pandemic news: Deer may provide a SARS-CoV-2 reservior; OSHA promulgates rules implementing the Biden administration’s workplace vaccine mandate; and a strong showing for Pfizer’s oral medication against SARS-CoV-2. Plus a frippery. Pfizer’s anti-Covid pill shows strong results … Continue reading →
